Metsera, Inc. Files 8-K: Other Events & Exhibits

TL;DR

Metsera filed an 8-K on Oct 29th for 'Other Events' and exhibits. Check it out.

AI Summary

Metsera, Inc. filed an 8-K on October 30, 2025, reporting an event on October 29, 2025. The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as key items. The company, incorporated in Delaware, is located at 3 World Trade Center, New York, NY.

Why It Matters

This 8-K filing signals that Metsera, Inc. has disclosed significant corporate events or financial information that could impact investors' understanding of the company's current status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and exhibits, not indicating any immediate negative news or significant financial distress.

Key Players & Entities

• Metsera, Inc. (company) — Registrant
• October 29, 2025 (date) — Earliest event reported
• October 30, 2025 (date) — Date of report
• 3 World Trade Center (location) — Principal executive offices
• New York (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.00001 — ich registered Common Stock, par value $0.00001 per share MTSR The Nasdaq Global Se
• $56.50 — would pay to Metsera an amount equal to $56.50 per Metsera common share in cash as wel
• $21.25 — representing the right to receive up to $21.25 in cash based on the achievement of cer
• $4.75 — ractual contingent right to receive (A) $4.75 per CVR in cash, without interest and l
• $10.00 — , on or prior to December 31, 2027; (B) $10.00 per CVR in cash without interest and le
• $6.50 — or prior to December 31, 2031; and (C) $6.50 per CVR in cash, without interest and l
• $190 million — ined in the Pfizer Merger Agreement) of $190 million to Pfizer simultaneously with the termi
• $227 million — yment to Novo Nordisk of a fee equal to $227 million and reimbursement to Novo Nordisk of th

Filing Documents

• d54035d8k.htm (8-K) — 52KB
• d54035dex991.htm (EX-99.1) — 17KB
• d54035dex992.htm (EX-99.2) — 616KB
• d54035dex993.htm (EX-99.3) — 53KB
• d54035dex994.htm (EX-99.4) — 141KB
• 0001193125-25-257435.txt ( ) — 1214KB
• mtsr-20251029.xsd (EX-101.SCH) — 3KB
• mtsr-20251029_lab.xml (EX-101.LAB) — 18KB
• mtsr-20251029_pre.xml (EX-101.PRE) — 11KB
• d54035d8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events On October 30, 2025, Metsera, Inc., a Delaware corporation (the "Company" or "Metsera"), issued a press release announcing that on October 29, 2025 the Metsera Board of Directors determined, after consultation with its outside counsel and financial advisors, that an unsolicited proposal that Metsera received from Novo Nordisk A/S, a Danish aktieselskab ("Novo Nordisk"), to acquire Metsera (the "Novo Nordisk Proposal") constitutes a "Superior Company Proposal" as defined in the Merger Agreement by and among Pfizer Inc. ("Pfizer"), a Delaware corporation, Mayfair Merger Sub, Inc. a Delaware corporation, and the Company (the "Pfizer Merger Agreement"). A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. Transaction Structure The Novo Nordisk Proposal is structured in two steps (together, the "Novo Nordisk Transaction"). In the first step, promptly following the signing of the Novo Transaction Agreements (as defined below), a Novo Nordisk subsidiary would pay to Metsera an amount equal to $56.50 per Metsera common share in cash as well as certain amounts in respect of Metsera employee equity and transaction expenses. In exchange, Metsera would issue Novo Nordisk shares of non-voting convertible preferred stock (the "Non-Voting Convertible Preferred Stock") representing, in the aggregate, 50% of Metsera's fully-diluted share capital on a post issuance basis. On the same day, Metsera would declare a dividend of $56.50 per Metsera common share, in cash, with a record date ten days following the signing of the Novo Merger Agreement with payment to follow in the days shortly thereafter. In the second step, which would happen only after receiving approval from Metsera shareholders and relevant regulators as well as the satisfaction of other customary conditions, holders of Metsera common stock and certain employee equity awards would receive one contingent value right ("CVR") per Metser

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including information about, among other topics, Pfizer's proposed acquisition of the Company, Pfizer's and the Company's pipeline products, including their potential benefits, potential best-in-class status, differentiation, profile and dosing, potential clinical trials, and the anticipated timing of completion of the proposed acquisition, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties relating to Pfizer's proposed acquisition of the Company include, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite vote by the Company stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that more competing offers may be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships, including the Company's ability to attract and retain highly qualified management and other clinical and scientific personals; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Pfizer's or the Company's common stock and/or operating results; significant transaction costs; unknown liabi

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. METSERA, INC. Date: October 30, 2025 By: /s/ Matthew Lang Matthew Lang Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR